Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20–26 years)

References

• Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660-4; PMID:25299412; http://dx.doi.org/10.1097/OLQ.0000000000000193
   PubMed Web of Science ®Google Scholar
• Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, et al. A review of human carcinogens–Part B: biological agents. Lancet Oncol. 2009;10(4):321-2; PMID:19350698; http://dx.doi.org/10.1016/S1470-2045(09)70096-8
   PubMed Web of Science ®Google Scholar
• de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56; PMID:20952254; http://dx.doi.org/10.1016/S1470-2045(10)70230-8
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-8; PMID:15863374; http://dx.doi.org/10.1016/S1470-2045(05)70101-7
   PubMed Web of Science ®Google Scholar
• Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GW, Ferris DG, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693-1702; PMID:17512854; http://dx.doi.org/10.1016/S0140-6736(07)60777-6
   PubMed Web of Science ®Google Scholar
• Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010; 341:c3493; PMID:20647284; http://dx.doi.org/10.1136/bmj.c5128
   PubMed Web of Science ®Google Scholar
• Palefsky JM, Giuliano AR, Goldstone S, Moreira ED Jr, Aranda C, Jessen H, Hillman R, Ferris D, Coutlee F, Stoler MH, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365(17):1576-85; PMID:22029979; http://dx.doi.org/10.1056/NEJMoa1010971
   PubMed Web of Science ®Google Scholar
• Powell SE, Hariri S, Steinau M, Bauer HM, Bennett NM, Bloch KC, Niccolai LM, Schafer S, Unger ER, Markowitz LE. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109-13; PMID:23137842; http://dx.doi.org/10.1016/j.vaccine.2012.10.092
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER; Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP). Quadrivalent human papillomavirus vaccine: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep. 2007; 56(RR-2):1-24; PMID:17380109
   PubMedGoogle Scholar
• Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28(30):4731-7; PMID:20188681; http://dx.doi.org/10.1016/j.vaccine.2010.02.019
   PubMed Web of Science ®Google Scholar
• Drolet M, Bénard É, Boily MC, Ali H, Baandrup L, Bauer H, Beddows S, Brisson J, Brotherton JM, Cummings T, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15(5):565-80; PMID:25744474
   PubMed Web of Science ®Google Scholar
• Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-802; PMID:23632723; http://dx.doi.org/10.1001/jama.2013.1625
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, Unger ER. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385-93; PMID:23785124; http://dx.doi.org/10.1093/infdis/jit192
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007;298(7):743-53; PMID:17699008; http://dx.doi.org/10.1001/jama.298.7.743
   PubMed Web of Science ®Google Scholar
• Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE. Prevalence of HPV infection among females in the United States. JAMA. 2007;297(8):813-9; PMID:17327523; http://dx.doi.org/10.1001/jama.297.8.813
   PubMed Web of Science ®Google Scholar
• Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006; 24 Suppl 3:S3/106-113; PMID:16949996
   PubMedGoogle Scholar
• Block SL, Nolan T, Sattler C, Barr E, Giacoletti KE, Marchant CD, Castellsagué X, Rusche SA, Lukac S, Bryan JT, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118(5):2135-45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7(12):1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
   PubMed Web of Science ®Google Scholar
• Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe. 2010;8(3):260-70; PMID:20833377; http://dx.doi.org/10.1016/j.chom.2010.08.003
   PubMed Web of Science ®Google Scholar
• Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol. 2011;85(24):13253-9; PMID:21976653; http://dx.doi.org/10.1128/JVI.06093-11
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199(7):936-44; PMID:19236277; http://dx.doi.org/10.1086/597309
   PubMed Web of Science ®Google Scholar
• Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, et al. Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1997-2008; PMID:25274978; http://dx.doi.org/10.1158/1055-9965.EPI-14-0410
   PubMed Web of Science ®Google Scholar
• Smolen KK, Gelinas L, Franzen L, Dobson S, Dawar M, Ogilvie G, Krajden M, Fortuno ES 3rd, Kollmann TR. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine. 2012;30(24):3572-3579; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
   PubMed Web of Science ®Google Scholar
• Schwarz T, Spaczynski M, Kaufmann A, Wysocki J, Gałaj A, Schulze K, Suryakiran P, Thomas F, Descamps D. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG. 2015;122(1):107-18; PMID:25208608; http://dx.doi.org/10.1111/1471-0528.13070
   PubMed Web of Science ®Google Scholar
• Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 2014;89(43):465-91; PMID:25346960
   PubMedGoogle Scholar
• National Health and Nutrition Examination Survey: Questionnaires, datasets, and related documentation. http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm. Accessed November 20, 2014.
   Google Scholar
• Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, Markowitz LE. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis. 2011;204(4):566-73; PMID:21791659; http://dx.doi.org/10.1093/infdis/jir341
   PubMed Web of Science ®Google Scholar
• Design and estimation for the National Health Interview Survey, 1995-2004. Vital Health Stat 2. 2000(130):1-31; PMID:AMBIGUOUS
   PubMedGoogle Scholar
• Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. Am J Public Health. 1991;81(9):1166-73; PMID:1951829; http://dx.doi.org/10.2105/AJPH.81.9.1166
   PubMed Web of Science ®Google Scholar
• Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, and risk ratios from complex survey data. Am J Epidemiol. 2010;171(5):618-23; PMID:20133516; http://dx.doi.org/10.1093/aje/kwp440
   PubMed Web of Science ®Google Scholar
• Norton EC, Miller MM, Kleinman LC. Computing adjusted risk ratios and risk differences in Stata. Stata Journal. 2013;13(3):492-509
   Web of Science ®Google Scholar